Ozempic

Ozempic (semaglutide) is a GLP-1 receptor agonist that mimics a natural hormone in your body. It works by slowing gastric emptying, reducing appetite, and helping regulate blood sugar levels. Originally developed for type 2 diabetes management, it has become widely prescribed off-label for weight loss due to the significant weight reduction observed in clinical trials.

In the STEP trials, patients taking semaglutide 2.4mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. Ozempic is dosed at lower levels (up to 2mg) than Wegovy (2.4mg), so weight loss results may vary. Many patients report noticeable appetite reduction within the first few weeks of treatment.

Ozempic is more commonly covered by insurance when prescribed for type 2 diabetes. Coverage for off-label weight loss use varies significantly by plan. Many insurers require prior authorization and documentation of BMI 30+ or BMI 27+ with a weight-related comorbidity. Without insurance, retail pricing typically ranges from $900-$1,400/month.

Compounded semaglutide contains the same active ingredient but is manufactured by compounding pharmacies rather than Novo Nordisk. Compounded versions typically cost 60-80% less but are not FDA-approved as a finished product. The FDA has raised concerns about compounded versions, though many physicians prescribe them as a more affordable alternative.